Xenon Pharmaceuticals is betting its future on whether a key epilepsy drug and a set of depression programs can deliver strong trial results and win over doctors who already have familiar options. The upside hinges on smooth late-stage progress and enough cash to reach launch without heavy fundraising, but weak data, slow real-world adoption, or higher costs could change the story.Read more
Xenon is betting its lead epilepsy medicine can become a go-to option for people whose seizures are hard to control, and then broaden into depression and bipolar depression to build a larger brain-health business. The upside hinges on late-stage trial results and whether doctors and insurers accept the drug as a safe, easy-to-use choice in crowded markets.Read more
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel targeted medicines for epilepsy, neuropsychiatric conditions and pain. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company’s Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
